钠-葡萄糖共转运蛋白2抑制剂治疗2型糖尿病合并非酒精性脂肪肝的研究进展

摘要

With the incidence of obesity and type 2 diabetes mellitus (T2DM) increasing dramatically worldwide,about 70％ of obese diabetics combined with non-alcoholic fatty liver disease (NAFLD) and even as many as 30％-40％ combined with non-alcoholic steatohepatitis (NASH).At present,T2DM with NAFLD has become one of the global health concerns.Even so,in recent years,a great deal of researches on sodium-glucose co-transporter 2 (SGLT2) inhibitors have shown that they have remarkable effect of lowering blood sugar,also,the incidence of adverse events related to liver has significantly reduced,thus providing new ideas for the treatment of NAFLD.%随着全球范围内肥胖和2型糖尿病(type 2 diabetes mellitus,T2DM)发病率的急剧增长,约70％的肥胖糖尿病患者同时合并有非酒精性脂肪肝(non-alcoholic fatty liver disease,NAFLD),甚至多达30％～40％的患者合并有非酒精性脂肪性肝炎(non-alcoholic steatohepatitis,NASH).目前T2DM合并NAFLD已成为全球关注的健康问题之一.尽管如此,近年来大量相关研究表明钠-葡萄糖共转运蛋白2(sodium-glucose co-transporter 2,SGLT2)抑制剂显著降糖的同时,肝相关不良事件的发生明显减少,为NAFLD的治疗提供了新思路.